Both in Biotechnology
Inhibrx Biosciences vs Monte Rosa Therapeutics
Over the past year INBX returned +5.8% and GLUE returned −9.8%; their daily moves had a correlation of 0.21.
INBX +5.8% GLUE −9.8%Growth of $1, one year, split-adjusted
| Metric | INBX | GLUE |
|---|---|---|
| Price | $86.76 | $10.82 |
| Market cap | $1.28B | $923.1M |
| Today | +7.01% | +3.94% |
| 1 month | −7.1% | +9.6% |
| 6 months | −38.8% | −46.9% |
| Year to date | +9.8% | −31.0% |
| 1 year | +6.5% | −10.4% |
| Revenue growth (YoY) | −100.0% | −61.3% |
| Gross margin | — | 100.0% |
| Net margin | — | −483.9% |
| P/E (TTM) | — | — |
| Price / sales | — | 32.1× |
| Net cash | -$42.9M | $621.1M |
| Dividend yield | — | — |
| Volatility (60d) | 88.8% | 53.3% |
| Short % of float | 35.5% | 41.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).